Omnicell Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/6/2026)
| Balance Sheet | Total Assets | 1,974,720,000.00 | Equity Ratio | 62.38 % |
| Balance Sheet | Total Equity | 1,231,810,000.00 | ROA | 0.10 % |
| Cashflow | Capital Expenditures | -40,415,000.00 | P/FCF | 20.29 |
| Cashflow | Free Cash Flow | 86,885,000.00 | – | – |
| Cashflow | Operating Cash Flow | 127,300,000.00 | P/CF | 13.85 |
| Income | Earnings per Share (diluted) | 0.04 | Div. Yield | – |
| Income | Net Income | 2,052,000.00 | P/E | 950.75 |
| Income | Shares Outstanding | 46,362,000.00 | P/B | 1.43 |
| Income | Total Revenue | 1,184,850,000.00 | P/S | 1.49 |
Ratios calculated on: 11/5/2026
Company Description
Omnicell, Inc. (Omnicell) is a provider of automated solutions for hospital medication and supply management. The Company´s automation and analytics solutions are designed to enable healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies. Its systems provide medication control and dispensing solution starting from the point of entry into the hospital and other health care providers, through the central pharmacy, to the nursing station and to the patient´s bedside. Omincell´s medication-use product line includes its OmniRx, SinglePointe, AnywhereRN, Anesthesia Workstation, WorkflowRx, Controlled Substance Management, OmniLinkRx, Savvy Mobile Medication System, and Pandora Data Analytics products. In May 2012, the Company acquired MTS Medication Technologies, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.omnicell.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more